MA32617B1 - Traitement de l'hypertension arterielle pulmonaire - Google Patents

Traitement de l'hypertension arterielle pulmonaire

Info

Publication number
MA32617B1
MA32617B1 MA33678A MA33678A MA32617B1 MA 32617 B1 MA32617 B1 MA 32617B1 MA 33678 A MA33678 A MA 33678A MA 33678 A MA33678 A MA 33678A MA 32617 B1 MA32617 B1 MA 32617B1
Authority
MA
Morocco
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
pulmonary
hypertension
Prior art date
Application number
MA33678A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Steve Pascoe
Deborah Quinn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32617(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32617B1 publication Critical patent/MA32617B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA33678A 2008-08-13 2011-03-07 Traitement de l'hypertension arterielle pulmonaire MA32617B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
MA32617B1 true MA32617B1 (fr) 2011-09-01

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33678A MA32617B1 (fr) 2008-08-13 2011-03-07 Traitement de l'hypertension arterielle pulmonaire

Country Status (16)

Country Link
US (1) US20110190313A1 (enExample)
EP (1) EP2315592A1 (enExample)
JP (1) JP2011530607A (enExample)
KR (1) KR20110053354A (enExample)
CN (1) CN102123711A (enExample)
AU (1) AU2009282104A1 (enExample)
BR (1) BRPI0917491A2 (enExample)
CA (1) CA2732789A1 (enExample)
CL (1) CL2011000295A1 (enExample)
IL (1) IL210922A0 (enExample)
MA (1) MA32617B1 (enExample)
MX (1) MX2011001668A (enExample)
NZ (1) NZ590839A (enExample)
RU (1) RU2011109078A (enExample)
TW (1) TW201010999A (enExample)
WO (1) WO2010019540A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
MX389551B (es) 2016-10-27 2025-03-20 Pulmokine Inc Politerapia para tratar hipertension pulmonar.
CA3042123A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
WO2020232238A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US20210154193A1 (en) * 2019-11-25 2021-05-27 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
AU2021339756A1 (en) * 2020-09-11 2023-04-13 Pulmosim Therapeutics Llc Compositions and methods for treating or preventing pulmonary hypertension
CA3199324A1 (en) 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
US20080114001A1 (en) * 2005-01-28 2008-05-15 Manley Paul W Use of Pyrimidylaminobenzamides for the Treatment of Diseases that Respond to Modulation of Tie-2 Kinase Activity
ES2593319T3 (es) * 2005-05-02 2016-12-07 Novartis Ag Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico
BRPI0619416A2 (pt) * 2005-12-06 2011-10-04 Novartis Ag derivados de pirimidilaminobenzamida para o tratamento da neurofibromatose
CN101622244A (zh) * 2006-11-03 2010-01-06 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物

Also Published As

Publication number Publication date
CN102123711A (zh) 2011-07-13
RU2011109078A (ru) 2012-09-20
CA2732789A1 (en) 2010-02-18
KR20110053354A (ko) 2011-05-20
JP2011530607A (ja) 2011-12-22
IL210922A0 (en) 2011-04-28
NZ590839A (en) 2013-02-22
TW201010999A (en) 2010-03-16
MX2011001668A (es) 2011-03-25
WO2010019540A1 (en) 2010-02-18
BRPI0917491A2 (pt) 2015-12-01
EP2315592A1 (en) 2011-05-04
US20110190313A1 (en) 2011-08-04
CL2011000295A1 (es) 2011-07-15
AU2009282104A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
MA32617B1 (fr) Traitement de l'hypertension arterielle pulmonaire
EP2338519A4 (en) MEANS FOR THE TREATMENT OF MYELOFIBROSIS
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EP2307035A4 (en) TREATMENT OF EPILEPSY
EP2637664A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION
EP1996612A4 (en) COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2046349A4 (en) TREATMENT OF EXCESSIVE NEOVASCULARIZATION
EP2154969A4 (en) TREATMENT OF SYNNUCLEOPATHY
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
EP2379084A4 (en) MODULATION OF THE EXPRESSION OF FACTOR 11
EP1982660A4 (en) TREATMENT ENDOSCOPE
EA201270575A1 (ru) Соединения
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
ATE479673T1 (de) Hemmer der neubildung menschlicher immundefekt- viren
EP2498796A4 (en) TREATMENT OF HEART DISEASES
EP2276795A4 (en) Processing biomass
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
EP1898930A4 (en) Treatment of inflammatory conditions
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
EP1744751A4 (en) METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES